Outcome of 5-Year Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Using "Treat and Extend" Regimen

Frontiers in Medicine
Polona Jaki Mekjavic, Polona Zaletel Benda

Abstract

The aim of this study is twofold. First, to evaluate the long-term outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in a clinical setting using the "treat-and-extend regimen" (TER) in patients with neovascular age-related macular degeneration (nAMD). Second, to determine the proportion of patients treated with anti-VEGF with good visual acuity (VA), i.e., vision sufficient to maintain a high level of independence. We conducted a single center retrospective review of patients with treatment-naive nAMD who were treated with anti-VEGF. Patients were treated with anti-VEGF intravitreal injections according to the TER. Patients started treatment with monthly injections of either bevacizumab (1.25 mg/0.05 mL) or ranibizumab (0.5 mg/0.05 mL) until there were no signs present of choroidal neovascularization (CNV) activity. CNV activity was determined from fundus examination and SD-OCT imaging. Follow-up administration of intravitreal injections was extended by 2-week intervals, up to a total of 14 weeks, provided no signs of CNV activity were detected. In some patients, the first treatment was replaced with aflibercept (2 mg/0.05 mL). On the basis of the inclusion criterion for the study, that patients had to be...Continue Reading

References

Nov 1, 1984·Archives of Ophthalmology·F L FerrisL Hyman
Mar 23, 2006·Current Opinion in Ophthalmology·Relief Jones, Douglas J Rhee
Mar 23, 2006·Current Opinion in Ophthalmology·James C H TanPaul L Kaufman
Jun 24, 2006·Current Opinion in Ophthalmology·Melissa M BrownGeorge R Beauchamp
Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Dec 23, 2006·Health and Quality of Life Outcomes·Jan Mitchell, Clare Bradley
Feb 2, 2011·Investigative Ophthalmology & Visual Science·Peggy OrrNeil M Bressler
Feb 15, 2011·Retina·Vikki A McBainNoemi Lois
Jan 17, 2012·Journal of Cataract and Refractive Surgery·Eva Mönestam, Britta Lundqvist
Jan 24, 2012·American Journal of Ophthalmology·Sara Brandi BlochInger Christine Munch
Jan 24, 2012·American Journal of Ophthalmology·Alon SkaatOfra Kalter-Leibovici
Jul 17, 2012·Neuron·Jayakrishna Ambati, Benjamin J Fowler
Oct 3, 2013·Ophthalmology·Juan E GrunwaldUNKNOWN CATT Research Group
Jan 28, 2014·Ophthalmology·UNKNOWN Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group
Jun 23, 2015·Ophthalmology·Mark C GilliesUNKNOWN Fight Retinal Blindness Study Group
May 10, 2016·Ophthalmology·UNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupStuart L Fine
Jun 4, 2016·Acta Ophthalmologica·Line KesselInger Christine Munch
Feb 13, 2017·Survey of Ophthalmology·Andrew S H TsaiChui Ming Gemmy Cheung

❮ Previous
Next ❯

Methods Mentioned

BETA
RAP

Software Mentioned

TER
SPSS

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.